Bifunctional Biologic Gets Orphan Drug Status for Paroxysmal Nocturnal Hemoglobinuria
The FDA has granted Orphan Drug designation to KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Source: empr.com
Page 3 - Frederick Beddingfield News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Frederick Beddingfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Frederick Beddingfield Today - Breaking & Trending Today
Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
/PRNewswire/ -- Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated...
Source: prnewswire.com
Bifunctional Biologic Gets Orphan Drug Status for Paroxysmal Nocturnal Hemoglobinuria
The FDA has granted Orphan Drug designation to KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Source: empr.com
Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China
Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China News provided by Share this article Share this article CAMBRIDGE, Mass. and SUZHOU, China, Feb. 23, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the addition of three seasoned pharmaceutical leaders, Kathy He, Richard Lee, MD, and Dana Zhang, MD, to its expanding team. Ms. He joins Kira as Chief Business Officer; D...
Source: prnewswire.com
Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated...
Source: prnewswire.com